Skip to main content

Cardiff Oncology, Inc 8-K, filed Oct 27, 2026

Cardiff Oncology, Inc. (CRDF)

8-K 2026-10-27 For: 2026-10-22
View Original
Added on October 27, 2026

About this 8-K

Cardiff Oncology, Inc filed this 8-K on October 27, 2026, reporting on events of October 22, 2026.

Cardiff Oncology appointed Leila Alland, MD, interim Chief Medical Officer on October 23, 2026, succeeding Roger Sidhu, MD, who separated October 22, 2026. The company also increased authorized common stock to 300,000,000 shares. AI summary

Items reported

  • Item 5.02: Director or officer change, or executive pay
  • Item 5.03: Charter or bylaw amendment, or fiscal year change
  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits